{"id":"NCT00095121","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B","officialTitle":"A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents (Age 2 to Less Than 18) With Chronic Hepatitis B","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-06","primaryCompletion":"2006-05","completion":"2010-04","firstPosted":"2004-11-01","resultsPosted":"2011-06-03","lastUpdate":"2012-05-22"},"enrollment":173,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis B"],"interventions":[{"type":"DRUG","name":"Placebo (PLB)","otherNames":[]},{"type":"DRUG","name":"Adefovir Dipivoxil (ADV)","otherNames":[]},{"type":"DRUG","name":"Lamivudine","otherNames":[]}],"arms":[{"label":"Placebo (PLB)","type":"PLACEBO_COMPARATOR"},{"label":"Adefovir Dipivoxil (ADV)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the efficacy and safety of adefovir dipivoxil for the treatment of chronic hepatitis B in children and adolescents (age 2 to less than 18 years) following 48 weeks of placebo-controlled, double-blind treatment and following an additional 192 weeks of open-label adefovir dipivoxil treatment.","primaryOutcome":{"measure":"Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 1000 Copies/mL (Polymerase Chain Reaction [PCR]-Based Assay) and Normal Alanine Aminotransferase (ALT) at Week 48 (Missing = Failure)","timeFrame":"Week 48","effectByArm":[{"arm":"Adefovir Dipivoxil (ADV)","deltaMin":0,"sd":null},{"arm":"Placebo (PLB)","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.gilead.com","http://www.gileadclinicaltrials.com/pdf/GS-US-103-0518_48wk_synopsis.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":115},"commonTop":["nasopharyngitis","pharyngitis","abdominal pain","headache","cough"]}}